ArticleCureus2025
Assessment of Immune Cell Populations in the Peripheral Blood of Patients With Metastatic Prostate Cancer.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Prostate cancer (PCa) encompasses a heterogeneous spectrum, ranging from indolent to highly aggressive forms, with approximately 10-20% of patients with initially localized disease later becoming metastatic. Oligometastatic PCa (OMPC) represents an intermediate state between locally advanced and high-volume metastatic disease. Understanding the immune landscape of OMPC and plurimetastatic PCa (PMPC) can provide valuable insights into disease biology, with potential implications for treatment strategies and prognosis. Aim and objective This study aimed to evaluate alterations in circulating immune cell subsets between OMPC and PMPC to identify potential immune biomarkers and therapeutic targets. Methods We conducted a retrospective cohort study of 43 mPC patients. Patients were stratified into two groups based on metastatic spread: OMPC (≤5 metastatic lesions in bone or lymph nodes) and PMPC (>5 lesions and/or visceral involvement). Peripheral blood mononuclear cells (PBMCs) were isolated and analyzed via flow cytometry for key immune subsets, including γδ T cells, αβ T cells, and regulatory T cells, with functional assessments performed using cytokine stimulation. Statistical analysis used the Mann-Whitney-Wilcoxon test, with p ≤ 0.05 considered significant. Results OMPC patients exhibited significantly increased γδ2+ T cells compared to PMPC, suggesting enhanced immune surveillance in low metastatic burden. A trend toward elevated γδ2+ T cells expressing interferon-gamma (IFN-γ) was observed in PMPC. No significant differences were observed in other immune subsets. Conclusions γδ2+ T cells represent a distinct immune subset in PCa, potentially influencing disease progression. Despite the small sample size, these findings highlight γδ2+ T cells as promising biomarkers and therapeutic targets. Prospective studies with a larger sample size are warranted to confirm the significance of these findings and explore the mechanistic roles of these cells and possible clinical applications in metastatic PCa (mPC).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.